Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Pifeltro (doravirine by Quarter
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Pifeltro (doravirine: 4.0% in Q4 2025, down 16.0 pts from a year earlier.
Latest, Q4 2025
4.0%
Period ended Dec 31, 2025
Change on a year earlier
-16.0 pts
20.0% in Q4 2024
History
6 quarters
Since Q1 2024
Sources
6
Documents cited below
Where the Q4 2025 figure comes from
“|| Pifeltro | 45 | 41 | 43 | 42 | 171 | 42 | 39 | 42 | 40 | 163 | 6 | 4 | 5 | 4”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 4.0% | -16.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | -1.0% | – | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 4.0% | 0.0 pts | Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 20.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 4.0% | – | Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗ |
| Q1 2024 | Mar 31, 2024 | 23.0% | – | Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗ |
Cite this data
StockData. (2026). Merck Pifeltro (doravirine (%), quarterly Q1 2024–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-pifeltro-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.